

December 6, 2024



PDRadiopharma Inc.

## PDRadiopharma announces listing of Techne® Pyrophosphate Injection on Japan National Health Insurance Drug Price List and Upcoming Market Launch

*\*This release is an English translation of “「テクネ®ピロリン酸静注」薬価基準収載および発売のお知らせ”, with a priority given to Japanese for content and interpretation. The indication is specifically for Japan only and not for other countries.*

TOKYO, JAPAN – December 6, 2024 – PDRadiopharma Inc. (President: Masato Murakami, Headquarters: Chuo-ku, Tokyo, Japan) announced today that **Techne® Pyrophosphate Injection** has been listed on the National Health Insurance (NHI) drug price standard in Japan. The product is scheduled for market launch on February 3, 2025.

Techne® Pyrophosphate Injection is a radiopharmaceutical intended for the diagnosis of bone disease by bone scintigraphy. PDRadiopharma has been marketing the **Techne® Pyrophosphate Kit**, which contains *technetium-99m pyrophosphate* as its active ingredient. This kit product has been used for the diagnosis of bone diseases by bone scintigraphy and the cardiac diseases by cardio scintigraphy.

The use of Techne® Pyrophosphate Injection for diagnosing bone diseases required the preparation of a mixture with *sodium pertechnetate (99mTc) injection* at medical institutions. To reduce radiation exposure and simplify the preparation process for healthcare professionals, PDRadiopharma received approval for a pre-mixed formulation in August 2024. This pre-mixed version will be available for release starting February 3, 2025.

For healthcare professionals handling radiopharmaceuticals, radiation protection is a critical consideration. PDRadiopharma remains committed to contributing to the advancement of healthcare and improving the well-being of individuals through the development of innovative pharmaceuticals.

### Product Overview

- Product name: Techne® Pyrophosphate Injection
- Generic name: flortaucipir F 18 injection
- Indication: Diagnosis of bone diseases by bone scintigraphy

### About PDRadiopharma

PDRadiopharma, a wholly-owned subsidiary of PeptiDream from 2022, has been providing high-quality radiopharmaceuticals through the research and development, manufacturing, regulatory and sales as a forerunner in the field of radiopharmaceuticals,

since it started its business in 1968. Currently PDRadiopharma offers 22 radiodiagnostic products (spanning both SPECT and PET products) and 8 radiotherapeutic products (3 product categories) in Japan. Additionally, PDRadiopharma and PeptiDream are developing a broad pipeline of radiotherapeutics and radiodiagnostics for both the Japan and global markets. For more information about PDRadiopharma, please visit [www.pdradiopharma.com](http://www.pdradiopharma.com)

Inquiries:

PDRadiopharma Inc.

Contact: Noriko Tanaka, General Affairs

Email: [s-info-hq@pdradiopharma.com](mailto:s-info-hq@pdradiopharma.com)